Literature DB >> 22590449

Are Three Weeks of Whole-Breast Radiotherapy as Good as Five Weeks in Early Breast Cancer? - 10 Year Follow-Up in the Canadian Trial of Hypofractionated Radiation Therapy.

.   

Abstract

Whole breast irradiation (WBI) is considered standard of care among both patients having undergone breast-conserving therapy for invasive breast carcinoma and selected cases post mastectomy. Since the introduction of WBI, clinical trials have been conducted to define the optimal dose, schedule and length of WBI aiming to increase efficacy while reducing toxicity. In the paper discussed in this issue's journal club, Whelan et al. present the latest in a series of randomized clinical trials on hypofractionated radiotherapy.

Entities:  

Year:  2010        PMID: 22590449      PMCID: PMC3346174          DOI: 10.1159/000319790

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  8 in total

1.  Hypofractionated radiotherapy for breast cancer.

Authors:  Joanne S Haviland; John R Yarnold; Søren M Bentzen
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

2.  Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.

Authors:  J Roger Owen; Anita Ashton; Judith M Bliss; Janis Homewood; Caroline Harper; Jane Hanson; Joanne Haviland; Soren M Bentzen; John R Yarnold
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

3.  Hypofractionation in radiotherapy for breast cancer.

Authors:  Harry Bartelink; Rodrigo Arriagada
Journal:  Lancet       Date:  2008-03-19       Impact factor: 79.321

Review 4.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

5.  Long-term results of hypofractionated radiation therapy for breast cancer.

Authors:  Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman
Journal:  N Engl J Med       Date:  2010-02-11       Impact factor: 91.245

6.  Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.

Authors:  John Yarnold; Anita Ashton; Judith Bliss; Janis Homewood; Caroline Harper; Jane Hanson; Jo Haviland; Søren Bentzen; Roger Owen
Journal:  Radiother Oncol       Date:  2005-03-16       Impact factor: 6.280

7.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

Authors:  S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; S M Bentzen; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold
Journal:  Lancet       Date:  2008-03-19       Impact factor: 79.321

8.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

Authors:  S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold
Journal:  Lancet Oncol       Date:  2008-03-19       Impact factor: 41.316

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.